Genomtec Past Earnings Performance
Past criteria checks 0/6
Genomtec has been growing earnings at an average annual rate of 1.1%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 94.6% per year.
Key information
1.1%
Earnings growth rate
15.4%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -94.6% |
| Return on equity | -86.1% |
| Net Margin | -549,850.0% |
| Next Earnings Update | 29 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Genomtec makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -11 | 11 | 0 |
| 31 Mar 24 | 0 | -10 | 10 | 0 |
| 31 Dec 23 | 0 | -9 | 9 | 0 |
| 30 Sep 23 | 0 | -13 | 10 | 0 |
| 30 Jun 23 | 0 | -12 | 9 | 0 |
| 31 Mar 23 | 0 | -13 | 9 | 0 |
| 31 Dec 22 | 0 | -12 | 9 | 0 |
| 30 Sep 22 | 0 | -8 | 6 | 0 |
| 30 Jun 22 | 0 | -7 | 6 | 0 |
| 31 Mar 22 | 0 | -6 | 5 | 0 |
| 31 Dec 21 | 0 | -7 | 5 | 0 |
| 30 Sep 21 | 0 | -14 | 12 | 0 |
| 30 Jun 21 | 0 | -14 | 12 | 0 |
| 31 Mar 21 | 0 | -12 | 12 | 0 |
| 31 Dec 20 | 0 | -11 | 11 | 0 |
Quality Earnings: 4VI is currently unprofitable.
Growing Profit Margin: 4VI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4VI is unprofitable, but has reduced losses over the past 5 years at a rate of 1.1% per year.
Accelerating Growth: Unable to compare 4VI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4VI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Return on Equity
High ROE: 4VI has a negative Return on Equity (-86.13%), as it is currently unprofitable.